AEGiS-14IAC: Switch to atazanavir from nelfinavir associated with cholesterol and triglyceride improvement: 12 wk results from BMS AI424-044.

14th International AIDS Conference

Barcelona, Spain - July 7-12, 2002

Switch to atazanavir from nelfinavir associated with cholesterol and triglyceride improvement: 12 wk results from BMS AI424-044.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. LbPeB9013)

Murphy R, Thiry A, Mancini M, Pokrovsky V, Rozenbaum W
Northwestern University, Chicago, IL, United States

BACKGROUND: Atazanavir (ATV) is a potent, safe, and effective QD PI in Phase III development. In AI424-008, ATV was associated with a lipid profile superior to nelfinavir (NFV). AI424-008 completers were treated with ATV/d4T/3TC in AI424-044: subjects on NFV switched to ATV 400 mg; subjects on ATV continued with ATV 400 or 600 mg. Changes in TC, HDL-C, fasting LDL-C, and fasting TG were assessed at 12 wks.

RESULTS: 346 subjects were treated. 3 ATV switch subjects discontinued for adverse events; none for virologic failure. [Image not included] *P<0.0001, #P<0.05 for Wk 12 vs entry

CONCLUSIONS: At 12 wks, NFV to ATV switch was associated with TC, LDL-C, and TG reductions, HDL-C increase, and decreased % of subjects with undesirable TC and LDL-C per NCEP. Improved lipids of this magnitude may reduce CV risk or need for dietary/pharmacologic interventions.

Keywords: AEGIS, Triglycerides, Nelfinavir, Cholesterol, Stavudine, Lipids, Lamivudine

020707
LbPeB9013